Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature

Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details

PubMedID
22304626

DOI
10.1111/j.1743-6109.2011.02615.x

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Carbolines /adverse effects /therapeutic use; Central Nervous System Diseases /complications; Clinical Trials as Topic; Humans; Imidazoles /adverse effects /therapeutic use; Impotence, Vasculogenic /drug therapy; Male; Multiple Sclerosis /complications; Parkinson Disease /complications; Phosphodiesterase 5 Inhibitors /adverse effects /therapeutic use; Piperazines /adverse effects /therapeutic use; Purines /adverse effects /therapeutic use; Sildenafil Citrate; Spinal Dysraphism /complications; Sulfones /adverse effects /therapeutic use; Tadalafil; Treatment Outcome; Triazines /adverse effects /therapeutic use; Vardenafil Dihydrochloride

AccessionNumber
12012020060

Date bibliographic record published
30/06/2012